Comparing the current results to its competitors, Myomo Inc reported Revenue increase in the 1 quarter 2026 by 3.04 % year on year. The revenue growth was below Myomo Inc 's competitors' average revenue growth of 10.51 %, achieved in the same quarter.
Myomo Inc 's Comment on Competition and Industry Peers
The company operates in a competitive and rapidly evolving industry. Its competitors may develop products that are safer, more effective, less costly, or easier to use, potentially affecting the company's market position. The company sells to orthotics and prosthetics (O&P) providers who may also market competing products. The market for myoelectric braces is relatively new with uncertain adoption rates. Competitors offering devices that enable patients with lower extremity paralysis to stand and walk include Lifeward, Ekso Bionics, and Cyberdyne. MicroTransponder, Inc. markets implanted devices that stimulate the vagus nerve to aid upper extremity movement recovery. New products competing with the company's MyoPro have been introduced by Neurolutions in the United States and by Vincent Systems and HKK Bionics in Germany. The company holds 35 issued patents covering the MyoPro Motion G product, which facilitates movement of multiple joints.
Overall company revenue, grew less, than total company revenues, at 3.04 % and company approximately market share, declined to 0.09 %. << More on MYO Market Share.
*Market share is calculated based on total revenue.
Microbot Medical Inc is a medical device company that focuses on the research, development, and commercialization of surgical solutions. Their business model revolves around creating innovative robotic technologies and tools for minimally invasive surgeries, catering to various medical specialties.
Stereotaxis Inc's business model involves developing and providing robotic technologies for use in medical procedures, particularly in the field of electrophysiology.
Sanuwave Health Inc operates through a business model centered on developing and commercializing innovative regenerative medicine technologies. The company focuses on creating noninvasive, nonthermal, and durable ultrasound therapeutic devices to treat various medical conditions. Sanuwave Health Inc primarily generates revenue by selling its products and securing licensing agreements with healthcare providers and distributors.
Insulet Corporation operates under a business model where they design, develop, and market innovative tubeless insulin delivery systems for people with diabetes. Their main product, the Omnipod System, is a wearable device that provides continuous insulin delivery without the need for traditional insulin pumps and tubing. This unique business model focuses on improving the quality of life for individuals with diabetes by offering a convenient and user-friendly insulin management solution.
Sources:
Myomo Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Myomo Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
